<DOC>
	<DOCNO>NCT00056134</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . Biological therapy denileukin diftitox may able deliver cancer-killing substance directly melanoma cell . Combining vaccine therapy biological therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine vaccine therapy denileukin diftitox treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy vaccination autologous dendritic cell pulse tumor influenza antigen peptide without ex vivo CD40-ligand denileukin diftitox , term tumor-specific T-cell response , patient HLA-A1- and/or HLA-A2.1-positive stage III IV melanoma . - Determine safety tolerability vaccination patient . - Determine tumor response patient treat vaccination . OUTLINE : - Phase I ( Administration denileukin diftitox vaccination # 1 # 4 ) : Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PMBC ) . PBMC process generation dendritic cell ( DC ) use vaccination . DC pulse HLA-A1- HLA-A2.1-restricted peptide derive melanoma-associated tumor antigen . DC pulse without ex vivo treatment CD40-ligand . Patients receive denileukin diftitox IV 3 consecutive day first vaccination . Patients receive 4 pulsed DC vaccination subcutaneously ( SC ) day 1 , 14 , 42 , 70 absence disease progression unacceptable toxicity . Patients show tumor response ( least stable disease ) may receive vaccination # 5 booster vaccination . - Phase II : DC generate pulsed phase I . Patients receive 6 additional booster pulse DC vaccination SC day 126 , 184 , 268 , 356 , 520 , 692 absence disease progession unacceptable toxicity . Patients follow 10 year . PROJECTED ACCRUAL : A total 8-30 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locoregional metastatic cutaneous malignant melanoma Stage III IV disease Stage III : pT4b , N0 , M0 ( satellite metastasis ) pT , N1 pT , N1 N2ac , M0 ( lymph node metastasis transit intralymphatic metastasis ) Stage IV : pT , N12 , M1ab Surgically incurable Incurable standard treatment ( i.e. , localize chemotherapy/limb perfusion stage III , systemic chemotherapy stage IV ) Unidimensionally bidimensionally measurable disease physical examination ( e.g. , cutaneous metastasis ) and/or noninvasive radiologic procedure NOTE : Stage III lesion may measurable lymph node incomplete resection and/or inoperable transit metastasis HLAA1 and/or HLAA2 expression serologic HLA type HLAA2.01 subtype must confirm polymerase chain reaction genomic DNA obtain peripheral blood mononuclear cell No active CNS metastases Previously treat CNS metastasis ( e.g. , excision single metastasis ) allow active disease present CT scan MRI PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 60100 % Life expectancy At least 6 month Hematopoietic WBC great 2,500/mm^3 Neutrophil count great 1,000/mm^3 Lymphocyte count great 700/mm^3 Platelet count great 75,000/mm^3 Hemoglobin great 9 g/dL No bleeding disorder Hepatic Bilirubin le 2.0 mg/dL No hepatitis B C Renal Creatinine le 2.5 mg/dL Cardiovascular No clinically significant heart disease Pulmonary No clinically significant respiratory disease Immunologic No active systemic infection No immunodeficiency disease No evidence HIV1 , HIV2 , human Tcell lymphocytic virus1 No active autoimmune disease include , limited : Lupus erythematosus Autoimmune thyroiditis uveitis Multiple sclerosis Inflammatory bowel disease NOTE : Vitiligo allow Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week study participation No organic brain syndrome significant psychiatric abnormality would preclude study participation followup No contraindication leukapheresis No active malignant neoplasm PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior systemic immunotherapy No concurrent immunotherapy 2 week last vaccination Chemotherapy See Disease Characteristics More 4 week since prior systemic chemotherapy ( 6 week nitrosoureas [ e.g. , fotemustine ] ) No concurrent chemotherapy 2 week last vaccination Endocrine therapy No concurrent corticosteroid 2 week last vaccination Radiotherapy No prior radiotherapy spleen Concurrent palliative radiotherapy allow select metastasis ( e.g. , pain local complication compression ) Surgery See Disease Characteristics Recovered prior surgery No prior splenectomy No prior organ allografts Concurrent surgery select metastasis ( e.g. , pain local complication compression ) allow Other No concurrent investigational drug 2 week last vaccination No concurrent paramedical substance 2 week last vaccination No concurrent participation intent participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>